Redefining the treatment of Chagas disease: a review of recent clinical and pharmacological data for a novel formulation of nifurtimox
Fig 1
Main metabolic pathways and resultant metabolites of nifurtimox [42, 43].
According to previous investigations, M-6 and M-4 were the only metabolites (among those quantified), that showed relevant plasma exposure in humans and exceeded or approached the guideline threshold of 10% of total exposure [42,44,45]. Please see the marketing authorization for further safety and drug–drug interaction testing [42,46]. *Indicates position of 14C label.